The group is recognized for developing the first-of-its-kind monoclonal antibody reference material, NISTmAb, which ensures the consistent, high-quality manufacture of state-of-the-art protein drugs used to treat intractable medical conditions such as cancer, autoimmune disorders, and infectious diseases. NISTmAb, the world's most highly characterized protein reference material, is a global benchmarking tool for the biopharmaceutical industry to assure protein drug product quality, evaluate the performance of new analytical tools, and support the development of new manufacturing technologies.